UK’s drugmaker AstraZeneca intends to develop between ten to fifteen new projects annually in China as part of its increased research and development initiatives. This strategic move was mentioned by the Sharon Barr, the executive vice-president of Biopharmaceuticals R & D during the talk with the media in Shanghai recently the company declared that this city was chosen to be the fifth strategic city in the world. In the Chinese region alone the company has more than 200 projects in the process of R&D and it seeks to recreate a unified global operation in development of drugs for common diseases such as cardiovascular diseases.

Shanghai site will be both research and commercial as well as production, which will make it strategic in AstraZeneca’s future business model. Barr also stressed that the company has a strategic focus on Shanghai in order to reach its goal of developing unique therapies.

AstraZeneca has also invested in numerous partnership with Biotech firms in purchasing out licences at worth of approximately $6.5 billion from the year starting 2023. Among them, three deals involving hypercholesterolemia, metabolic diseases and cell therapy are worth $2 billion in total and improve the company’s ability to advance the creation of meaningful therapies faster.

Earlier this year, AstraZeneca successfully organized the R&D China Science Day in Shanghai and its theme was “Addressing the Lives of Chronic and Rare Diseases Patients.” Several other thousand individuals attended the meeting; experts as well as leaders in the medical arena, to indicate the rising role of science those years in the region. In the future, the company is focused on providing at least 100 new medicines or indications on the Chinese market in the nearest five years, proving its concern with healthcare all around the world.